Issue 4 2019

14 CORPORATE VISION / Issue 4 2019 , Tenthpin is a global management consulting firm, with deep expertise in the Life Sciences Industry sectors. Recently, the firm found success in CV’s Corporate Excellence Awards 2019 where they were selected as the Leading Specialists in Technology Consulting 2019 - Life Sciences. On the back of this win, we profile Tenthpin and caught up withMichael Schmidt, Partner and Co-Founder, who provided us with a glimpse into the innerworkings of the successful firmand the outstanding services they provide. Making the Difference Established in 2017, Tenthpin’s ambition is to be the leading business and technol- ogy consultancy that understands the unique challeng- es within the different industry segments in Life Sciences. Providing independent advice and services to clients, Tenthpin com- bines their industry and process knowledge with the latest technol- ogy drivers, making the difference in any transformational change. Founded by five ex-big four con- sultants, Tenthpin’s overall mission is to make a difference in Life Sciences. Going into further detail, Michael begins by informing us of the clients the firm serves, and the steps the team takes to ensure they deliver an exceptional service to those they work alongside. “Here at Tenthpin, we work along- side many of the world’s Top 20 companies in Pharma, Biotech, Medical Technologies and Animal Health. In addition to this, we also work with smaller Biotech start- ups, CROs, Pharma Distributors and Healthcare organizations. “Given that Tenthpin is a new brand, we are investing a lot into initial client meetings to introduce our people and our services. Our story resonates extremely well with the market, as a result we have built up a client base of more than 30 clients since our founda- tion. Currently, our project portfolio includes lots of M&A work for two of the leading Animal health companies, designing and imple- menting SAP global templates for a number of large, global Pharma and Med Device companies, de- livering industry specific solutions like e-labeling for clinical trials, building an analytics factory for a leading Pharma company, and many more. Most of all, we love asking our potential clients to give us their most difficult projects and/ or business challenges.” Speaking of the services they provide to their clients, the team at Tenthpin have deep Life Science’s industry experience and global reach, as well as the capability to transform organizations with leading edge technology and pro- cess knowledge. The passionate, enthusiastic, dedicated and high- ly-experienced team which forms the backbone of Tenthpin plays a vital role in the overall success of the firm, as Michael explains. “At Tenthpin, our people are abso- lutely key to our overall success. Consulting is a people business, and our people make the differ- ence. They are passionate about clients, whilst being enthusiasts for consulting but most of all are committed to achieving success.” Looking ahead to what the future holds, the team at Tenthpin will continue to deliver their exception- al services which have seen them receive numerous accolade since the company got founded, with their most recent success of being recognised in Corporate Vision’s Corporate Excellence Awards 2019 where they were awarded the accolade Leading Special- ists in Technology Consulting 2019 - Life Sciences. Bringing the interview to a close, Michael signs off by revealing what the future has in store for not only the team at Tenthpin, but also the Life Sciences Industry sectors. “Moving forwards, we will continue to grow our global footprint, as well as extending our service portfolio further to meet the current and future needs of the Life Sciences industries. “The introduction of value-based models and risk-based pricing has changed the way drugs or medical devices are being evaluated. This healthcare value chain trans- formation is driven by the need to reduce expenditures, as well as to provide new, personalized treatments to patients, such as cell and gene therapies. How- ever, ‘personalized medicine’ requires a fundamentally different end-to-end capability towards a truly patient-centric analysis and response across the entire value chain. In addition to launching new treatments in the market, pharma- ceutical organizations struggle to implement integrated supply chain capabilities. In a nutshell, technol- ogy is evolving faster than the life sciences industry can cope with.” Apr19025